Brokerages predict that TESARO Inc (NASDAQ:TSRO) will report ($2.44) earnings per share for the current fiscal quarter, according to Zacks. Nine analysts have made estimates for TESARO’s earnings. The highest EPS estimate is ($2.17) and the lowest is ($2.89). TESARO reported earnings per share of ($3.35) during the same quarter last year, which would indicate a positive year over year growth rate of 27.2%. The firm is scheduled to issue its next quarterly earnings report on Tuesday, February 26th.

On average, analysts expect that TESARO will report full year earnings of ($10.87) per share for the current year, with EPS estimates ranging from ($11.37) to ($10.10). For the next fiscal year, analysts anticipate that the company will post earnings of ($9.05) per share, with EPS estimates ranging from ($11.07) to ($7.80). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that cover TESARO.

TESARO (NASDAQ:TSRO) last issued its earnings results on Thursday, November 1st. The biopharmaceutical company reported ($2.49) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($2.62) by $0.13. TESARO had a negative net margin of 295.67% and a negative return on equity of 1,209.72%. The firm had revenue of $64.40 million during the quarter, compared to analyst estimates of $71.84 million. During the same quarter in the prior year, the business earned ($0.47) earnings per share. TESARO’s revenue for the quarter was down 54.9% on a year-over-year basis.

A number of equities analysts recently weighed in on the stock. ValuEngine upgraded shares of TESARO from a “hold” rating to a “buy” rating in a research report on Tuesday. Wedbush restated an “outperform” rating on shares of TESARO in a research report on Tuesday, November 13th. Royal Bank of Canada dropped their target price on shares of TESARO to $38.00 and set a “sector perform” rating for the company in a research report on Friday, August 3rd. Jefferies Financial Group dropped their target price on shares of TESARO from $38.00 to $25.00 and set a “hold” rating for the company in a research report on Monday, November 12th. Finally, BidaskClub upgraded shares of TESARO from a “buy” rating to a “strong-buy” rating in a research report on Friday, October 19th. Eight equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. TESARO presently has an average rating of “Buy” and a consensus target price of $73.25.

Institutional investors have recently added to or reduced their stakes in the stock. KBC Group NV raised its stake in shares of TESARO by 20.0% in the second quarter. KBC Group NV now owns 10,533 shares of the biopharmaceutical company’s stock valued at $468,000 after acquiring an additional 1,752 shares during the period. Rhumbline Advisers raised its stake in shares of TESARO by 5.0% in the second quarter. Rhumbline Advisers now owns 39,787 shares of the biopharmaceutical company’s stock valued at $1,769,000 after acquiring an additional 1,885 shares during the period. Commonwealth Equity Services LLC raised its stake in shares of TESARO by 13.4% in the third quarter. Commonwealth Equity Services LLC now owns 18,822 shares of the biopharmaceutical company’s stock valued at $734,000 after acquiring an additional 2,218 shares during the period. Trellus Management Company LLC raised its stake in shares of TESARO by 20.0% in the second quarter. Trellus Management Company LLC now owns 13,819 shares of the biopharmaceutical company’s stock valued at $615,000 after acquiring an additional 2,300 shares during the period. Finally, US Bancorp DE raised its stake in shares of TESARO by 163.5% in the third quarter. US Bancorp DE now owns 3,940 shares of the biopharmaceutical company’s stock valued at $153,000 after acquiring an additional 2,445 shares during the period.

Shares of NASDAQ:TSRO traded up $5.72 during midday trading on Tuesday, reaching $42.55. 199,924 shares of the company were exchanged, compared to its average volume of 2,636,409. The company has a debt-to-equity ratio of 3.74, a quick ratio of 2.83 and a current ratio of 3.40. TESARO has a one year low of $23.41 and a one year high of $88.83. The firm has a market cap of $1.92 billion, a price-to-earnings ratio of -4.63 and a beta of 1.35.

TESARO Company Profile

Tesaro, Inc, an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting.

Featured Story: What is a stock buyback?

Get a free copy of the Zacks research report on TESARO (TSRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.